Forecast

There is no analyst data available for this company.

News Go to news feed

CSL writes down around $5 billion and lowers FY26 guidance

CSL is taking a one‑off impairment of about $5 billion on intangibles from the acquisition of CSL Vifor and has cut its adjusted earnings guidance for FY26 to $3.1–3.2 billion, with expected revenue of roughly $15.2 billion. The shares plunged; results are being hit by inventory normalization for immunoglobulins in the US, price declines for albumin in China, and increased competitive and geopolitical pressure. Management plans a transformation program targeting $500–550 million in annual savings by 2028, while market observers are assessing whether cuts could slow mRNA research (including collaborations via CSL Seqirus/CureVac) and thereby hand competitive advantages to BioNTech. » More on finanzen.net
CSL to spin off Seqirus as US vaccine fatigue fades, CEO says

CSL CEO Paul McKenzie said the time is right to spin off its Seqirus business as vaccine demand grows and US vaccine "fatigue" eases, particularly among older people. The announcement comes after CSL's shares plunged the most in 23 years following disappointing earnings results. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, CSL ADR has already paid €0.27 in dividends. The last payout was in April.

Financials

In the last quarter, CSL ADR had revenue of €6.52B and net profit of -€2.62B

(EUR)	June 2026	YoY
Revenue	6.52B	-
Gross profit	2.89B	-
Net profit	-2.62B	-
EBITDA	1.72B	-

Fundamentals

Metric	Value
Market capitalization	€102.37B
Number of shares	3.87B
52-week high/low	€31.32 - €13.82
Dividend yield	2.28%
Dividends TTM	€0.62
Beta	0.08
P/E ratio	-23.23
PEG ratio	0.13
P/B ratio	3.98
P/S ratio	3.74

Company profile

CSL Limited erforscht, entwickelt, produziert, vermarktet und vertreibt biopharmazeutische und verwandte Produkte in Australien, den Vereinigten Staaten, Deutschland, dem Vereinigten Königreich, der Schweiz, China und international. Das Unternehmen ist in zwei Segmenten tätig, CSL Behring und Seqirus. Das Segment CSL Behring bietet Plasmatherapien an, wie z. B. Plasmaprodukte und Rekombinanten für die Behandlung von Immunschwäche, Blutungsstörungen, hereditärem Angioödem, Alpha-1-Antitrypsin-Mangel und neurologischen Störungen. Dieses Segment betreibt auch Forschung auf dem Gebiet der Plasma- und Nicht-Plasma-Therapien und erhält Lizenzen und Tantiemen aus der Vermarktung von geistigem Eigentum. Das Segment Seqirus produziert und vertreibt biotherapeutische Nicht-Plasmaprodukte und entwickelt Produkte zur Behandlung von Grippe. CSL Limited wurde 1916 gegründet und hat seinen Hauptsitz in Parkville, Australien.